New pharmacologic approaches to treating diabetic retinopathy (Q33295160)

25 July 2017

1 reference

title

New pharmacologic approaches to treating diabetic retinopathy (English)

1 reference

25 July 2017

1 reference

1 reference

Gina J Ryan

1

1 reference

25 July 2017

1 September 2007

1 reference

American Journal of Health-System Pharmacy

25 July 2017

1 reference

25 July 2017

64

1 reference

25 July 2017

17 Suppl 12

1 reference

25 July 2017

S15-21

1 reference

Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy

25 July 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Aldose reductase in diabetic microvascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Molecular understanding of hyperglycemia's adverse effects for diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

PKC-B inhibition: a new therapeutic approach for diabetic complications?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Recent clinical experience with aldose reductase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized cl

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Inhibition of microvascular endothelial cell migration by β-cyclodextrin tetradecasulfate and hydrocortisone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070332

31 March 2020

Identifiers

DOI

10.2146/AJHP070332

1 reference

25 July 2017

1 reference

PubMed ID

17720889